Literature DB >> 12898579

Association between human mu-opioid receptor gene polymorphism, pain tolerance, and opioid addiction.

Peggy Compton1, Daniel H Geschwind, Maricela Alarcón.   

Abstract

Central to both pain responses and opioid addiction is activity at the micro -opioid receptor. To explore the role of the micro -opioid receptor gene (OPRM) in human pain tolerance and opioid addiction, we examined the relationships among OPRM genotype and experimental pain tolerance in opioid addicts in methadone treatment (n = 50) and healthy normal controls (n = 59). Pain phenotype (pain tolerant vs. pain intolerant) was operationalized as tolerance to a standardized noxious stimulus (either thermal or mechanical), and dichotomized based on distribution. One microsatellite and two single nucleotide polymorphisms, A118G and C17T, in exon 1 were typed to study the OPRM gene. Although the established relationship between the phenotypes of opioid addiction and pain intolerance was validated (P = 0.02), genotype differed neither between addict-affected vs. control, nor pain tolerant vs. intolerant subjects. The variant A118G was absent in all individuals and the C17T polymorphism appeared in only three African-American individuals (two addicts and one control). The absence of this polymorphism, the small sample size and the heterogeneous ethnic backgrounds of participants in the pilot study allow only tentative conclusions based on the results, thus the role of the opioid receptor in pain and opioid reward response remains uncertain. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12898579     DOI: 10.1002/ajmg.b.20057

Source DB:  PubMed          Journal:  Am J Med Genet B Neuropsychiatr Genet        ISSN: 1552-4841            Impact factor:   3.568


  18 in total

1.  Association between two mu-opioid receptor gene (OPRM1) haplotype blocks and drug or alcohol dependence.

Authors:  Huiping Zhang; Xingguang Luo; Henry R Kranzler; Jaakko Lappalainen; Bao-Zhu Yang; Evgeny Krupitsky; Edwin Zvartau; Joel Gelernter
Journal:  Hum Mol Genet       Date:  2006-02-13       Impact factor: 6.150

Review 2.  Cellular signalling of non-synonymous single-nucleotide polymorphisms of the human μ-opioid receptor (OPRM1).

Authors:  Alisa Knapman; Mark Connor
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

3.  Pharmacological consequence of the A118G μ opioid receptor polymorphism on morphine- and fentanyl-mediated modulation of Ca²⁺ channels in humanized mouse sensory neurons.

Authors:  Saifeldin Mahmoud; Annika Thorsell; Wolfgang H Sommer; Markus Heilig; Joan K Holgate; Selena E Bartlett; Victor Ruiz-Velasco
Journal:  Anesthesiology       Date:  2011-11       Impact factor: 7.892

4.  Genetic influences on the dynamics of pain and affect in fibromyalgia.

Authors:  Patrick H Finan; Alex J Zautra; Mary C Davis; Kathryn Lemery-Chalfant; Jonathan Covault; Howard Tennen
Journal:  Health Psychol       Date:  2010-03       Impact factor: 4.267

5.  A6V polymorphism of the human μ-opioid receptor decreases signalling of morphine and endogenous opioids in vitro.

Authors:  Alisa Knapman; Marina Santiago; Mark Connor
Journal:  Br J Pharmacol       Date:  2015-03-17       Impact factor: 8.739

Review 6.  Molecular mechanisms of opioid receptor-dependent signaling and behavior.

Authors:  Ream Al-Hasani; Michael R Bruchas
Journal:  Anesthesiology       Date:  2011-12       Impact factor: 7.892

7.  Mouse model of OPRM1 (A118G) polymorphism has sex-specific effects on drug-mediated behavior.

Authors:  Stephen D Mague; Carolina Isiegas; Peng Huang; Lee-Yuan Liu-Chen; Caryn Lerman; Julie A Blendy
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-15       Impact factor: 11.205

Review 8.  Genetic contributions to pain: a review of findings in humans.

Authors:  R B Fillingim; M R Wallace; D M Herbstman; M Ribeiro-Dasilva; R Staud
Journal:  Oral Dis       Date:  2008-11       Impact factor: 3.511

Review 9.  Tolerance and withdrawal from prolonged opioid use in critically ill children.

Authors:  Kanwaljeet J S Anand; Douglas F Willson; John Berger; Rick Harrison; Kathleen L Meert; Jerry Zimmerman; Joseph Carcillo; Christopher J L Newth; Parthak Prodhan; J Michael Dean; Carol Nicholson
Journal:  Pediatrics       Date:  2010-04-19       Impact factor: 7.124

Review 10.  An Expert Review of Pharmacogenomics of Sickle Cell Disease Therapeutics: Not Yet Ready for Global Precision Medicine.

Authors:  Khuthala Mnika; Gift D Pule; Collet Dandara; Ambroise Wonkam
Journal:  OMICS       Date:  2016-09-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.